Article Text

Download PDFPDF

Small bowel & nutrition free papers
OC-082 26-Week efficacy and safety of once-daily oral linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a European perspective
  1. A J Lembo1,
  2. J Fortea2,
  3. C Diaz2,
  4. M Falques2,
  5. J Z Shao3,
  6. B J Lavins3,
  7. H A Schneier4,
  8. J M Johnston3
  1. 1Beth Israel Deaconess Medical Center, Boston, USA
  2. 2Almirall, Barcelona, Spain
  3. 3Ironwood Pharmaceuticals, Cambridge, UK
  4. 4Forest Research Institute, Jersey City, USA


Introduction Linaclotide, a minimally absorbed guanylate cyclase-C receptor agonist, is an investigational drug treatment for IBS-C. As part of the European Medicines Authority submission we evaluated the efficacy and safety of linaclotide 290 μg, administered once daily for 26 weeks (wks), in a Phase 3 trial of patients with IBS-C.

Methods In a randomised, double-blind, Phase 3 trial, IBS-C patients (modified Rome II criteria) with an overall complete spontaneous bowel movement (CSBM) frequency of <3/wk, an overall spontaneous bowel movement (SBM) frequency of ≤5/wk and an average abdominal pain score of ≥3 (0–10 scale) during a 2 wk baseline period were randomised to linaclotide or placebo for 26 wks of treatment. Efficacy parameters were analysed at 12 and 26 wks.

Results In total, 804 patients (female 90%; median age 44 years) received linaclotide (n=401) or placebo (n=403). During the 2 wk baseline period, 87% had abdominal pain every day (mean score 5.6; 0–10 scale) and 76% had no CSBMs (mean rate 0.2/wk). Significant improvements in linaclotide-treated patients were seen for both co-primary and all 12 secondary parameters. For the first co-primary parameter (≥30% reduction from baseline in mean abdominal pain or discomfort score with neither score worsening for ≥6 of the first 12 wks), 54.1% of linaclotide-treated patients and 38.5% of placebo-treated patients were responders (p<0.0001). For the second co-primary parameter (“considerably relieved” or “completely relieved” on the weekly degree-of-relief of IBS symptoms question for ≥6 of the first 12 wks), 39.4% of linaclotide-treated patients and 16.6% of placebo-treated patients were responders (p<0.0001). Similar improvements in both co-primary endpoints were seen at 26 wks (53.6% vs 36.0%, 37.2% vs 16.9%; both p<0.0001). Also, rates for sustained abdominal pain/discomfort response and sustained IBS degree-of-relief response at 12 and 26 wks were significantly greater in linaclotide-treated vs placebo-treated patients (all p<0.0001). Linaclotide significantly improved CSBMs, stool consistency, straining, bloating, SBMs, abdominal pain and abdominal discomfort vs placebo over 12 and 26 wks (p<0.0001). The most common adverse event (AE) was diarrhoea, causing discontinuation in 4.0% of linaclotide-treated and 0.2% of placebo-treated patients.

Conclusion Treatment of IBS-C with linaclotide produced statistically significant improvements in abdominal and bowel symptoms at 12 wks and were sustained over 26 wks. Diarrhoea was the most common AE.

Competing interests A J Lembo grant/research support from: Ironwood Pharmaceuticals, consultant for: Ironwood Pharmaceuticals/Salix/Prometheus/Alkermes/Ardelyx/GSK/Theravance, conflict with: lecture fees from Ironwood Pharmaceuticals, J Fortea Shareholder with: Almirall, Employee of: Almirall, C Diaz Employee of: Almirall, M Falques Employee of: Almirall, J Shao Employee of: Ironwood Pharmaceuticals, B J Lavins Employee of: Ironwood Pharmaceuticals, H A Schneier Employee of: Forest Research Institute, J M Johnston Employee of: Ironwood Pharmaceuticals.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.